熱門資訊> 正文
Schrödinger扩大了Bristol Myers Squibb与人工智能联合科学家的合作伙伴关系
2026-08-05 21:14
- Schrödinger (SDGR) announced on Wednesday a strategic agreement with Bristol Myers Squibb to deploy its Bunsen agentic AI co-scientist across the company's research organization.
- The deal expands the companies' long-standing partnership and broadens the use of Schrödinger's computational platform in drug discovery.
- Schrödinger will work with Bristol Myers Squibb to add new features to Bunsen and connect it with its RetroSynth AI platform for molecule design and synthesis planning.
- Chief Scientific Officer Robert Abel said the agreement will help more scientists adopt AI and computational tools to accelerate drug discovery.
More on Schrödinger
- Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It
- Schrödinger: Surviving, If Not Thriving, In The Tricky AI Drug Discovery Field
- Schrödinger, Inc. (SDGR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Schrödinger Q2 2026 Earnings Preview
- Seeking Alpha’s Quant Rating on Schrödinger
推薦文章
港股周報 | 黃金股狂飆！靈寶黃金周升24%；段永平「被動減持」泡泡瑪特；藥明康德升近20%創新高
一周財經日曆 | 重磅財報周！騰訊、Lumentum、中芯國際輪番登場！美國7月CPI攜零售數據來襲
8月8日外盤頭條：伊朗內部辯論霍爾木茲協議措辭 非農爆冷削弱加息預期 SpaceX將自建發電廠保障電力供應
Palantir股價將創下自2024年以來最佳單周表現，該股已不再是AI領域的失意者
7月非農就業數據走弱，支持美聯儲維持利率不變，但加息選項並未徹底排除
美股前瞻 | 聚焦20：30！市場靜候7月非農數據；特朗普政府擬加碼佈局關鍵礦產；應用光電計劃大規模擴產，光通信盤前集體飆升
港股異動 | 創新葯概念再度走強，再鼎新葯勁升14%，Q2產品收入環比增長11%；藥明生物升逾5%，百濟神州升逾3%
港股異動 | AI硬件股多數上漲，建滔積層板、勝宏科技漲逾5%，兆易創新漲逾3%；南方兩倍做多海力士跌逾9%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
